Will a lab test take us a step closer to "personalized medicine"? Approval of a genetic assay for drug utilization suggests so

Article

The US Food and Drug Administration has approved a genetics-based test that detects how certain drugs are utilized in the body. The Invader UGT1A1 Molecular Assay detects variations in the gene UGT1A1, which produces an enzyme that is active in the metabolism of certain drugs, including irinotecan (Camptosar), used to treat colorectal cancer.

Recent Videos
Geetika Kennady, MD, FAAP
Jillian Cotter, MD
Jesse Hinckley, MD, PhD
Validating digital stethoscope for pediatric breath sounds, with Jennifer Nestor, MD
Decreasing antibiotics for acute otitis media and community acquired pneumonia, with Elysha Pifko, MD
Sensory play for children with autism, with Joshua Feder, MD
Stephanie Chao, MD
Feasibility of ambulatory blood pressure monitoring in primary care | Carissa Baker-Smith, MD, MPH
Tina Tan, MD
Camille Walker CPNP-PC, MSN, CPNP Sacheen D. Harris MSN, CPNP-PC
Related Content
Diagnose this 18-day-old female with apnea, cyanosis, decreased feeding concerns

Diagnose this 18-day-old female with apnea, cyanosis, decreased feeding concerns

Akash Deswaney, MD;Neil Copeland, MD;John Bishara, DO
May 5th 2025
Article

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Site Logo

Food Insecurity and the Dangers of Infant Formula Dilution

January 30th 2023
Podcast
Mona Shahriari, MD previews Revolutionizing Atopic Dermatitis 2025

Mona Shahriari, MD previews Revolutionizing Atopic Dermatitis 2025

Mona Shahriari, MD, FAAD
May 2nd 2025
Article

Mona Shahriari, MD, discusses how RAD 2025 can equip providers with tools to improve atopic dermatitis outcomes.

Demystifying Infant Formula

Demystifying Infant Formula

October 11th 2022
Podcast
Nirsevimab shows strong real-world effectiveness against RSV in infants | Image credit: © Peter Hansen - stock.adobe.com.

Nirsevimab shows strong real-world effectiveness against RSV in infants

Morgan Ebert, Managing Editor
May 1st 2025
Article

Nirsevimab significantly reduces RSV-related hospitalizations, ICU admissions, and LRTIs in infants, but doesn’t shorten hospital stays, according to a recent study.

FDA news in pediatrics: April 2025 | Image Credit: © Araki Illustrations - © Araki Illustrations - stock.adobe.com.

FDA news in pediatrics: April 2025

Morgan Ebert, Managing Editor
May 1st 2025
Article

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from April 2025.

© 2025 MJH Life Sciences

All rights reserved.